Term Infants Fed Human Milk-Based Fortifier
Achieved Full Enteral Feeds 30 Days Sooner and Experienced Better
Weight Gain Compared to Infants Fed Cow Milk-Based
Fortifier
DUARTE, Calif., May 15, 2024 /PRNewswire/ -- Prolacta
Bioscience, the world's leading hospital provider of 100% human
milk-based nutritional products, announced today that data
demonstrating the benefits of Prolacta's Exclusive Human Milk Diet
(EHMD) for term infants recovering from gastroschisis repair
surgery will be presented at the European Society for Paediatric
Gastroenterology Hepatology and Nutrition (ESPGHAN) meeting in
Milan, Italy, taking place
May 15-18.
Gastroschisis is a birth defect in which the intestines, and
sometimes other organs, protrude through a hole in the abdominal
wall. Infants recovering from gastroschisis repair, especially
those with complex disease and comorbidities (e.g., heart or lung
disease), require high macronutrient intake for optimal
growth.1 Clinicians are increasingly addressing this
nutritional need through human milk fortification, which means
adding a fortifier to mother's own milk or donor milk to provide
additional calories and protein. Until recently, fortification was
primarily with cow milk-based fortifiers or formula. These
fortifiers have been associated with feeding intolerance and
necrotizing enterocolitis (NEC) in preterm
infants.2-4
The ESPGHAN poster presentation "Human Milk-Based Fortifiers
Associated With Improved Growth and Shorter Time to Full Enteral
Feeds in Term Infants After Gastroschisis Repair" includes data
from a case-control study showing:
- Term infants who received an EHMD with Prolacta's human
milk-based fortifier formulated for term infants achieved full
enteral feeds 30 days sooner than infants who received cow
milk-based fortifiers or formula (adjusted p = 0.004).
- The EHMD-fed cohort also experienced higher weight gain
velocity (adjusted p = 0.049) and less NEC, with no adverse events
reported.
"Term infants who require surgery often experience poor growth
and significant morbidities when a cow milk-based nutritional
fortifier is used," said study lead author Dr. Heidi Karpen of the Emory
University School of Medicine. "Safe and early postsurgical
fortification with an EHMD helps address the specific feeding
challenges impacting these infants. It also supports growth and
decreases the risk of NEC, which may translate into improved
long-term neurodevelopmental outcomes."
"This pioneering study for infants with gastroschisis reaffirms
the critical importance of optimal nutrition for the growth and
health of medically fragile infants," noted Melinda Elliott, MD, FAAP, practicing
neonatologist and chief medical officer for Prolacta. "It is
well-established in the medical community and in hospitals across
the country that Prolacta's EHMD is beneficial for extremely low
birth weight premature infants. This data demonstrates that the
benefits extend to term infants who require surgery for
gastroschisis repair."
The ESPGHAN annual meeting is at the forefront of education
provision and knowledge exchange. To register for the ESPGHAN
meeting, click here.
About Prolacta's Human Milk-Based Nutritional
Products
Available to hospitals since 2006,
Prolacta's human milk-based fortifiers changed the standard of care
for critically ill, premature infants by providing a proven
alternative to cow milk-based fortifiers in the NICU.4-6
The naturally occurring bioactive components in human milk are
thought to support infants' immunity, development, growth, and
long-term health.7
Prolacta's products have the highest bioactivity in the human
milk industry8 and are clinically proven to
significantly boost human milk bioactive proteins and antioxidant
activity.9 The company's proprietary processing ensures
pathogen inactivation and the highest level of safety while
retaining as much of the natural bioactivity of the milk as
possible, compared to other human milk processing
methods.8,10,11
About Prolacta Bioscience
Prolacta Bioscience® is a global life sciences company
dedicated to Advancing the Science of Human Milk® to
improve health outcomes for critically ill and premature infants.
As the world's leading provider of human milk-based nutritional
products for hospitals, Prolacta has touched the lives of more
than 100,000 premature infants worldwide.12 Prolacta's
human milk-based products have been evaluated in more than 20
peer-reviewed clinical studies, and hospitals adopting Prolacta's
Exclusive Human Milk Diet realize up to a 3X dollar-for-dollar
return on investment.13 Operating the world's first
pharmaceutical-grade human milk processing facilities, Prolacta
maintains the industry's strictest quality and safety standards,
with over 20 validated tests for screening and testing human milk.
Prolacta's manufacturing process uses vat pasteurization to ensure
pathogen inactivation while protecting nutritional composition and
bioactivity. Learn more at www.prolacta.com, on X, Instagram,
Facebook, and LinkedIn.
Media Contact:
Loren
Kosmont
Lkosmont@prolacta.com
310-721-9444
References
1. Riddle S, Karpen H. Special populations-surgical
infants. Clin Perinatol. 2023;50(3):715-728.
doi:10.1016/j.clp.2023.04.008
2. Hair AB, Peluso AM, Hawthorne KM, et al. Beyond
necrotizing enterocolitis prevention: improving outcomes with an
exclusive human milk-based diet [published correction appears in
Breastfeed Med. 2017 Dec;12 (10):663]. Breastfeed
Med. 2016;11(2):70-74. doi:10.1089/bfm.2015.0134
3. Assad M, Elliott MJ, Abraham JH. Decreased cost and improved
feeding tolerance in VLBW infants fed an exclusive human milk diet.
J Perinatol. 2016;36(3):216-220. doi:10.1038/jp.2015.168
4. Sullivan S, Schanler RJ, Kim JH, et al. An exclusively
human milk-based diet is associated with a lower rate of
necrotizing enterocolitis than a diet of human milk and bovine
milk-based products. J Pediatr. 2010;156(4):562-567.e1.
doi:10.1016/j.jpeds.2009.10.040
5. Abrams SA, Schanler RJ, Lee ML, Rechtman DJ. Greater
mortality and morbidity in extremely preterm infants fed a diet
containing cow milk protein products. Breastfeed Med.
2014;9(6):281-285. doi:10.1089/bfm.2014.0024
6. Cristofalo EA, et al. Randomized trial of exclusive human
milk versus preterm formula diets in extremely premature infants.
J Pediatr. December 2013.
163(6):1592-1595. doi: 10.1016/j.jpeds.2013.07.011
7. Gila-Diaz A, Arribas SM, Algara A, Martín-Cabrejas MA,
López de Pablo ÁL, Sáenz de Pipaón M, Ramiro-Cortijo D. A review of bioactive factors
in human breastmilk: a focus on prematurity. Nutrients.
2019;11(6):1307. doi:10.3390/nu11061307
8. Liang N, Koh J, Kim BJ, Ozturk G, Barile D, Dallas DC.
Structural and functional changes of bioactive proteins in donor
human milk treated by vat-pasteurization, retort sterilization,
ultra-high-temperature sterilization, freeze-thawing and
homogenization. Front. Nutr.
2022;9. https://doi.org/10.3389/fnut.2022.926814
9. Philip RK, Romeih E, Bailie E, et al. Exclusive human
milk diet for extremely premature infants: a novel fortification
strategy that enhances the bioactive properties of fresh, frozen,
and pasteurized milk specimens. Breastfeed Med. April
2023;18(4):279-290. http://doi.org/10.1089/bfm.2022.0254
10. Meredith-Dennis L, Xu G, Goonatilleke E, Lebrilla CB,
Underwood MA, Smilowitz JT. Composition and variation of
macronutrients, immune proteins, and human milk oligosaccharides in
human milk from nonprofit and commercial milk banks. J Hum
Lact. 2018;34(1):120-129. doi:10.1177/0890334417710635
11. Lima HK, Wagner-Gillespie M, Perrin MT, Fogleman AD.
Bacteria and bioactivity in Holder pasteurized and shelf-stable
human milk products. Curr Dev Nutr. 2017;1(8):e001438.
doi:10.3945/cdn.117.001438
12. Data on file; estimated number of premature infants
fed Prolacta's products from January
2007 to August 2023.
13. Swanson JR, Becker A, Fox J, et al. Implementing an
exclusive human milk diet for preterm infants: real-world
experience in diverse NICUs. BMC Pediatr. 2023;23(1).
doi.org/10.1186/s12887-023-04047-5
View original content to download
multimedia:https://www.prnewswire.com/news-releases/study-shows-exclusive-human-milk-diet-benefits-term-infants-post-gastroschisis-repair-data-to-be-presented-at-espghan-2024-meeting-302146395.html
SOURCE Prolacta Bioscience